News and Announcements
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) receives $2.2 million R&D cash rebate
- Published February 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Australian oncology-focused biotechnology company, Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) has received a $2.2 million R&D cash rebate.
The ASX listed company is pleased to confirm they received $2,191,257.95 from the Australian Taxation Office under the R&D tax Incentive Program for the financial year ending 30 June 2018.
Kazia CEO, Dr James Garner, said: ““The R&D tax rebate is an important, non-dilutive source of funding for the Company.”
“The amount is consistent with the expectations laid out in our financial reports, and the funds will be invested in progressing our two clinical programs.”
“This is an important year for Kazia, with multiple data read-outs anticipated in the near future.”
About Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
